Xceleron was founded in 1997 in York, UK and has since expanded its operations with a US facility in Maryland, providing bioanalytical accelerator mass spectrometry (AMS) services for accelerated early drug development.

The company pioneered human microdose and microtracer techniques using ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It has been providing drug development services for more than 10 years and has conducted more GLP and GCP studies than any other CRO of its type, with unmatched robust analytical processes and knowledge of experimental design.

“…incorporating 14C microtracer into Phase1 provides valuable understanding of [Candidate Drug] with minimal cost/effort impact on the overall programme” – Andy Gray, Global Project Manager, AZ

“The IV microtracer design may be the most important/influential” – Graeme Young, DMPK, GSK

Xceleron’s experience is especially valuable today because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.

>> See how our microtracer/AMS techniques have helped 6 drugs to reach market.
>> Read this recent report in Bioanalysis: Pfizer recommends AMS for better drug development paradigms/protocols.
>> Contact us to see how we can help your drug development program